title: [Long-term therapy of cancer pain. A controlled study on buprenorphine].
abstract: Sublingual tablets of buprenorphine (Temgesic sublingual) were given in a controlled trial of 41 patients for 2804 patient-days. With a mean starting dose of 1.09 mg and a final dose of 1.53 mg buprenorphine daily there was a good pain-relieving effect. The interval between doses was six to eight hours. The trial did not reveal any direct pointers as to tolerance or addictiveness after long-term intake of the drug. Because of its effectiveness and good duration of action, as well as the absence of negative long-term effects, the drug can be recommended in the long-term management of cancer pain.
authors.forename: M
authors.initials: M
authors.lastname: Zenz
authors.forename: S
authors.initials: S
authors.lastname: Piepenbrock
authors.forename: M
authors.initials: M
authors.lastname: Tryba
authors.forename: M
authors.initials: M
authors.lastname: Glocke
authors.forename: M
authors.initials: M
authors.lastname: Everlien
authors.forename: W
authors.initials: W
authors.lastname: Klauke
mesh_terms: D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D008134:Long-Term Care; D009019:Morphinans / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications*; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology; D010166:Palliative Care
chemical_list: D009019:Morphinans; D002047:Buprenorphine
vernacular_title: Langzeittherapie von Krebsschmerzen. Kontrollierte Studie mit Buprenorphin.